Biochemistry Paper 1 — Short Notes

BIOCHEMISTRY
PAPER 1 — SHORT NOTES
Model Answers — First Year MBBS
TN MGR Medical University
Based on Saranified Predictions 2026 (3rd Edition) — cross-referenced with D.M. Vasudevan, Textbook of Biochemistry for
Medical Students

51 Short Notes | 6 Marks Each | Point-wise Format

Includes original flowcharts, pathway diagrams and reference values

How to use this document

Each answer is written point-wise for quick revision and structured to fit a 6-mark short note. Orange boxes highlight
reference/normal values wherever applicable to the topic. Diagrams are original schematic flowcharts drawn
specifically for these topics (not sourced images) to keep labelling exam-accurate and copyright-clean.

Page 1
 Biochemistry Paper 1 — Short Notes

Enzymes & Bioenergetics

Q1. Inhibitors of ETC (6 marks)

Reference values: Normal ETC generates ~28 ATP per glucose via oxidative phosphorylation (out of ~30-32 total)

• Electron Transport Chain (ETC) inhibitors act at specific complexes of the inner mitochondrial membrane, blocking
electron flow and consequently ATP synthesis.
• Complex I (NADH-CoQ reductase) inhibitors: Rotenone (fish/plant poison, also a pesticide), Amytal (barbiturate),
and other rotenoids — block electron transfer from NADH to CoQ.
• Complex II (Succinate-CoQ reductase) inhibitors: Malonate (competitive inhibitor of succinate dehydrogenase),
Carboxin, TTFA — block FADH2 pathway.
• Complex III (Cytochrome bc1) inhibitors: Antimycin A (antibiotic), British Anti-Lewisite (BAL/Dimercaprol) — block
electron transfer between cytochrome b and c1.
• Complex IV (Cytochrome oxidase) inhibitors: Cyanide, Azide, Carbon monoxide, Hydrogen sulphide — bind the
ferric (Fe3+) haem-a3/CuB centre, preventing O2 reduction; classic poisons causing cytotoxic (histotoxic) hypoxia.
• ATP synthase (Complex V) inhibitor: Oligomycin — blocks the F0 proton channel, stopping ATP synthesis while still
allowing a proton gradient to build up.
• Uncouplers (distinct from inhibitors): 2,4-Dinitrophenol (DNP) and physiological uncoupling protein thermogenin
(UCP1 in brown fat) dissipate the H+ gradient without blocking carriers — electron transport continues but energy
is released as heat, not trapped as ATP.
• Clinical relevance: cyanide poisoning is treated with amyl nitrite/sodium nitrite (forms methaemoglobin, which
binds cyanide) followed by sodium thiosulphate (converts cyanide to thiocyanate via rhodanese).

Q2. Chemiosmotic theory of ATPase / oxidative phosphorylation (6 marks)

Reference values: Proposed by Peter Mitchell (1961, Nobel Prize 1978); ~2.5 ATP per NADH, ~1.5 ATP per FADH2

• Chemiosmotic theory explains how the energy of electron transport is coupled to ATP synthesis via a proton
gradient across the inner mitochondrial membrane.
Page 2
 Biochemistry Paper 1 — Short Notes
• As electrons pass through Complexes I, III and IV, protons (H+) are actively pumped from the matrix into the
intermembrane space.
• This creates an electrochemical gradient (proton-motive force) — a combination of a pH gradient (matrix alkaline)
and a membrane potential (matrix negative, ~-160 mV).
• The inner mitochondrial membrane is impermeable to H+ except through the specific F0 channel of ATP synthase.
• ATP synthase (Complex V) has two components: F0 (membrane-embedded proton channel) and F1 (matrix-facing
catalytic head with alpha3beta3gamma subunits).
• As protons flow back down their gradient through F0 into the matrix, the energy released drives rotation of the
gamma subunit within F1, causing conformational changes (binding change mechanism, Boyer) in the beta
subunits that catalyse ADP + Pi -> ATP.
• This process is termed 'chemiosmotic coupling' because a chemical reaction (ATP synthesis) is driven by an
osmotic/ionic gradient.
• Clinical correlation: uncouplers (DNP) and inhibitors of the F0 channel (oligomycin) demonstrate that electron
transport and ATP synthesis, though normally coupled, are mechanistically separable processes.

Q3. Analytical uses of enzymes with examples (6 marks)

• Enzymes are widely used as analytical tools in clinical laboratories owing to their high specificity and sensitivity,
allowing measurement of substrates, products, or the enzymes themselves.
• Diagnostic enzymology: measuring serum enzyme levels helps localize tissue damage — e.g., raised AST/ALT in
liver disease, CK-MB and Troponin-associated assays in myocardial infarction, Amylase/Lipase in acute
pancreatitis, Alkaline phosphatase in bone/liver disease, Acid phosphatase in prostatic carcinoma.
• Enzymes as reagents for estimating metabolites: Glucose oxidase-peroxidase (GOD-POD) method for blood
glucose estimation; Cholesterol oxidase for serum cholesterol; Urease for blood urea estimation; Uricase for uric
acid.
• Coupled enzyme assays: e.g., hexokinase/glucose-6-phosphate dehydrogenase coupled method gives a more
specific glucose estimate by linking to NADPH generation measured spectrophotometrically at 340 nm.

Page 3
 Biochemistry Paper 1 — Short Notes
• Enzyme immunoassays (EIA/ELISA): enzymes such as horseradish peroxidase or alkaline phosphatase are
conjugated to antibodies/antigens to quantify hormones, tumour markers, and infectious disease antigens with
high sensitivity.
• Enzymes in molecular biology/genetic engineering: restriction endonucleases (cut DNA at specific sites), DNA
ligase (joins fragments), DNA polymerase/Taq polymerase (PCR), reverse transcriptase (cDNA synthesis) —
foundational tools for recombinant DNA technology.
• Therapeutic/analytical enzyme use: Streptokinase/urokinase (thrombolysis), L-asparaginase (leukemia
treatment), and enzymes used in biosensors (e.g., glucometers use immobilized glucose oxidase).
• Enzymes also assist in clinical chemistry automation, enabling rapid, specific, cost-effective, and reproducible
quantitative assays.

Q4. Isoenzymes (6 marks)

Reference values: LDH1-LDH5 (5 isoenzymes); CK-MM, CK-MB, CK-BB

• Isoenzymes (isozymes) are multiple physically distinct forms of the same enzyme that catalyse the same reaction
but differ in physical/chemical properties such as electrophoretic mobility, Km, and tissue distribution.
• They usually arise because the enzyme is a multimeric (oligomeric) protein made of two or more types of
polypeptide subunits encoded by different genes, which combine in various proportions.
• Classic example — Lactate Dehydrogenase (LDH): a tetramer of H (heart) and M (muscle) subunits, giving 5
isoenzymes — LDH1 (H4), LDH2 (H3M), LDH3 (H2M2), LDH4 (HM3), LDH5 (M4).
• LDH1 predominates in heart and RBCs; LDH5 predominates in liver and skeletal muscle. In myocardial infarction,
LDH1 > LDH2 (flipped pattern).
• Creatine Kinase (CK): dimer of M and B subunits — CK-MM (skeletal muscle), CK-MB (cardiac muscle, raised
specifically in MI), CK-BB (brain).
• Alkaline phosphatase isoenzymes differ by tissue of origin (liver, bone, intestine, placenta) and can be
distinguished by heat stability, electrophoresis, or specific inhibitors.
• Isoenzymes are identified/separated by electrophoresis (differing net charge), chromatography, immunological
methods, or differential heat/chemical inactivation.
• Clinical significance: isoenzyme patterns help pinpoint the tissue of origin of an elevated total enzyme level, aiding
diagnosis (e.g., CK-MB and Troponin for MI, ALP isoenzymes to distinguish bone vs liver disease, LDH pattern in
haemolysis/MI/liver disease).

Q5. Non-competitive enzyme inhibition — kinetics with an example (6 marks)

Reference values: Vmax decreases; Km unchanged

• Non-competitive inhibition occurs when an inhibitor binds to a site on the enzyme distinct from the active site (an
allosteric site), and can bind either the free enzyme (E) or the enzyme-substrate complex (ES).
• Because the inhibitor does not compete with substrate for the active site, it binds equally well whether or not
substrate is present, and cannot be overcome by increasing substrate concentration.
• The inhibitor causes a conformational change that reduces catalytic efficiency (kcat) without necessarily
preventing substrate binding.
• Kinetics: Vmax decreases (fewer functional enzyme molecules effectively available), while Km remains unchanged
(substrate affinity for active site is not affected).
• On a Lineweaver-Burk plot, lines with and without inhibitor intersect on the x-axis (same x-intercept = -1/Km) but
have different y-intercepts (1/Vmax increases with inhibitor, since Vmax falls).
• Example: Heavy metal ions (Hg2+, Pb2+, Ag+) bind sulfhydryl (-SH) groups of enzymes, causing non-competitive
inhibition of many enzymes.

Page 4
 Biochemistry Paper 1 — Short Notes
• Another classic example: cyanide's inhibition of cytochrome oxidase, and inhibition of some enzymes by chelation
of essential metal cofactors, illustrate this pattern.
• Clinically, understanding this type of inhibition helps explain drug/toxin actions where increasing substrate does
not reverse toxicity, unlike competitive inhibitors, guiding management of certain poisonings.

Q6. Substrate-level phosphorylation — define with clear biochemical examples (6

marks)
Reference values: Yields 4 ATP directly in glycolysis (net 2); 1 GTP in TCA cycle per turn

• Substrate-level phosphorylation (SLP) is the direct transfer of a high-energy phosphate group from a
phosphorylated metabolic intermediate to ADP (or GDP), forming ATP (or GTP), without involvement of the
electron transport chain or a membrane-bound proton gradient.
• It occurs in the cytosol as well as in mitochondria, and does not require oxygen — hence it continues even under
anaerobic conditions.
• Example 1 — Glycolysis: Phosphoglycerate kinase transfers a phosphate from 1,3-bisphosphoglycerate to ADP,
forming 3-phosphoglycerate and ATP.
• Example 2 — Glycolysis: Pyruvate kinase transfers a phosphate from phosphoenolpyruvate (PEP) to ADP, forming
pyruvate and ATP — this is a highly exergonic, essentially irreversible step.
• Example 3 — TCA cycle: Succinyl-CoA synthetase (succinate thiokinase) converts succinyl-CoA to succinate,
transferring energy to GDP to form GTP (which can be converted to ATP by nucleoside diphosphate kinase).
• Contrast with oxidative phosphorylation: SLP directly transfers phosphate from a substrate to ADP, whereas
oxidative phosphorylation generates ATP indirectly via the proton-motive force created by the ETC.
• Significance: SLP allows a small but crucial yield of ATP (net 2 ATP per glucose in glycolysis) even in the absence of
oxygen (e.g., in exercising muscle, RBCs which lack mitochondria), making it essential for anaerobic energy
metabolism.
• In total aerobic glucose oxidation, SLP contributes a minor fraction of ATP compared to oxidative
phosphorylation, but it is indispensable when oxygen supply is limited.

Q7. Suicide enzyme inhibition with suitable clinical examples (6 marks)

• Suicide inhibition (mechanism-based inhibition) is a special type of irreversible inhibition in which the inhibitor is
structurally similar to the normal substrate and is initially processed by the enzyme's normal catalytic mechanism.
• During catalysis, the enzyme converts the inhibitor into a highly reactive intermediate that then covalently and
irreversibly binds to the active site, permanently inactivating the enzyme (the enzyme 'commits suicide' by acting
on it).
• Because the inhibitor mimics the substrate, it is highly specific for the target enzyme, minimizing off-target effects
— a useful pharmacological property.
• Clinical example 1: Aspirin (acetylsalicylic acid) irreversibly acetylates a serine residue in the active site of
cyclooxygenase (COX-1/COX-2), permanently inhibiting prostaglandin/thromboxane synthesis — basis of its
antiplatelet action.
• Clinical example 2: Allopurinol is converted by xanthine oxidase into alloxanthine (oxypurinol), which remains
tightly bound to the enzyme, inhibiting further uric acid production — used in gout treatment.
• Clinical example 3: Penicillin acts as a suicide inhibitor of bacterial transpeptidase (penicillin-binding protein)
involved in cell wall synthesis, forming a stable, inactive enzyme-penicillin complex.
• Clinical example 4: 5-Fluorouracil is converted to FdUMP, which forms a covalent, irreversible complex with
thymidylate synthase, blocking DNA synthesis — used as an anticancer/antimetabolite drug.
• Because inhibition is irreversible, enzyme activity is restored only by synthesis of new enzyme molecules, giving
these drugs a prolonged duration of action compared to reversible inhibitors.

Page 5
 Biochemistry Paper 1 — Short Notes
Q8. Types of enzyme inhibition (Competitive vs Non-competitive) with graphs and
their impact on Km and Vmax (6 marks)
Reference values: Competitive: Km up, Vmax unchanged | Non-competitive: Km unchanged, Vmax down

• Competitive inhibition: the inhibitor closely resembles the substrate structurally and binds reversibly to the same
active site, competing directly with substrate for enzyme binding.
• Effect can be overcome by increasing substrate concentration, since sufficient substrate can outcompete the
inhibitor for the active site.
• Kinetic effect: apparent Km increases (lower apparent affinity), while Vmax remains unchanged (at very high [S],
full activity can still be achieved).
• Lineweaver-Burk plot: lines with and without inhibitor intersect on the y-axis (same 1/Vmax) but have different
slopes/x-intercepts.
• Example: Malonate competitively inhibiting succinate dehydrogenase; statins competitively inhibiting HMG-CoA
reductase; methotrexate competing with folate for dihydrofolate reductase.
• Non-competitive inhibition: inhibitor binds to a site distinct from the active site (allosteric site), on either free
enzyme or enzyme-substrate complex, and is not overcome by increasing substrate concentration.
• Kinetic effect: Vmax decreases (fewer catalytically active enzyme molecules effectively present), while Km is
unchanged (affinity for substrate at the active site is unaffected).
• Lineweaver-Burk plot: lines intersect on the x-axis (same -1/Km) with differing y-intercepts (higher 1/Vmax with
inhibitor present); example — heavy metals binding -SH groups.

Q9. Mitochondrial shuttle systems — transport of cytoplasmic NADH into

mitochondria and net ATP yield (6 marks)
Reference values: Malate-aspartate shuttle: 2.5 ATP/NADH | Glycerol-3-phosphate shuttle: 1.5 ATP/NADH

• The inner mitochondrial membrane is impermeable to NADH generated in the cytosol during glycolysis, so
specialized shuttle systems are required to transfer its reducing equivalents into the mitochondrial matrix.

Page 6
 Biochemistry Paper 1 — Short Notes
• Malate-Aspartate Shuttle (predominant in liver, kidney, and heart): cytoplasmic NADH reduces oxaloacetate to
malate (via cytosolic malate dehydrogenase); malate crosses the inner membrane via the malate-
alphaketoglutarate antiporter.
• Inside the matrix, malate is reoxidized to oxaloacetate by mitochondrial malate dehydrogenase, regenerating
NADH which feeds directly into Complex I of the ETC.
• Oxaloacetate (which cannot cross the membrane) is transaminated to aspartate, which is transported back to the
cytosol (via the aspartate-glutamate antiporter) and reconverted to oxaloacetate, completing the cycle.
• This shuttle is reversible and yields the full ~2.5 ATP per NADH, since NADH is regenerated directly in the matrix
and donates electrons to Complex I.
• Glycerol-3-Phosphate Shuttle (predominant in skeletal muscle and brain): cytosolic NADH reduces
dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate via cytosolic glycerol-3-phosphate dehydrogenase.
• Glycerol-3-phosphate is reoxidized by a mitochondrial (FAD-linked) glycerol-3-phosphate dehydrogenase located
on the outer face of the inner membrane, directly reducing FAD to FADH2, which feeds electrons into the ETC at
the level of CoQ (bypassing Complex I).
• This shuttle is irreversible and yields only ~1.5 ATP per cytoplasmic NADH (since electrons enter at CoQ, not
Complex I) — less efficient in ATP yield, but faster, favouring tissues with high, rapid energy demand.

Page 7
 Biochemistry Paper 1 — Short Notes

Carbohydrate Metabolism
Q1. Significance of HMP shunt pathway (6 marks)

Reference values: G6PD deficiency: most common human enzyme defect worldwide, X-linked

• The Hexose Monophosphate (HMP) shunt/Pentose Phosphate Pathway is an alternate glucose oxidation pathway
occurring in the cytosol, active in liver, adrenal cortex, adipose tissue, RBCs, lactating mammary gland, and testes.
• It has an oxidative phase (irreversible): glucose-6-phosphate -> 6-phosphogluconate -> ribulose-5-phosphate,
catalysed by Glucose-6-phosphate dehydrogenase (G6PD, rate-limiting enzyme) and 6-phosphogluconate
dehydrogenase, generating 2 NADPH.
• Non-oxidative phase (reversible): transketolase and transaldolase interconvert 3-7 carbon sugars, allowing flexible
production of ribose-5-phosphate or return of intermediates to glycolysis.
• Significance 1 — NADPH production: essential reducing power for reductive biosynthesis of fatty acids,
cholesterol, and steroid hormones.
• Significance 2 — Ribose-5-phosphate production: required for nucleotide, DNA, and RNA synthesis (used in
rapidly dividing cells).
• Significance 3 — Antioxidant defense: NADPH maintains reduced glutathione (via glutathione reductase), which
detoxifies peroxides via glutathione peroxidase, protecting RBC membranes and haemoglobin from oxidative
damage.
• Significance 4 — NADPH is required by cytochrome P450 mono-oxygenase systems (drug/steroid metabolism)
and by NADPH oxidase in phagocytes for the respiratory burst (microbial killing).
• Clinical correlation: G6PD deficiency (X-linked) impairs NADPH generation, predisposing RBCs to oxidative
haemolysis on exposure to oxidant drugs (antimalarials, sulfonamides), fava beans, or infection — causing
haemolytic anaemia with Heinz bodies.

Page 8
 Biochemistry Paper 1 — Short Notes

Q2. Fate of pyruvate (6 marks)

• Pyruvate, the end product of glycolysis, occupies a central metabolic crossroad and can follow several pathways
depending on tissue, oxygen availability, and metabolic state.
• 1. Reduction to Lactate: under anaerobic conditions (e.g., vigorously exercising muscle, RBCs lacking
mitochondria), lactate dehydrogenase (LDH) reduces pyruvate to lactate, regenerating NAD+ needed to sustain
glycolysis.
• 2. Oxidative decarboxylation to Acetyl-CoA: under aerobic conditions, pyruvate enters mitochondria and is
irreversibly converted to acetyl-CoA by the pyruvate dehydrogenase complex (requires thiamine pyrophosphate,
lipoic acid, CoA, FAD, NAD+); acetyl-CoA then enters the TCA cycle for complete oxidation.
• 3. Carboxylation to Oxaloacetate: pyruvate carboxylase (biotin-dependent, mitochondrial) converts pyruvate to
oxaloacetate — an anaplerotic reaction replenishing TCA cycle intermediates and the first step of
gluconeogenesis.
• 4. Transamination to Alanine: alanine aminotransferase (ALT) reversibly transfers an amino group to pyruvate,
forming alanine — important in the glucose-alanine cycle transporting nitrogen from muscle to liver.
• The pathway chosen depends on the cell's energy status, oxygen availability, and hormonal signals (e.g., insulin
favours acetyl-CoA formation/oxidation; glucagon/fasting favours gluconeogenic flux).
• Clinical relevance: pyruvate dehydrogenase deficiency causes lactic acidosis and neurological impairment, since
pyruvate is diverted to lactate instead of entering the TCA cycle.
• Understanding pyruvate's fate is essential to grasp the interlinking of glycolysis, TCA cycle, gluconeogenesis, and
amino acid metabolism.

Page 9
 Biochemistry Paper 1 — Short Notes

Q3. Von Gierke's syndrome (6 marks)

Reference values: Type I Glycogen Storage Disease; severe fasting hypoglycaemia

• Von Gierke's disease is Type I Glycogen Storage Disease (GSD-I), caused by deficiency of glucose-6-phosphatase
(Type Ia) or the glucose-6-phosphate transporter (Type Ib) in liver, kidney, and intestinal mucosa.
• Glucose-6-phosphatase is essential for the final step of both glycogenolysis and gluconeogenesis — converting
glucose-6-phosphate to free glucose for release into the blood; its absence blocks hepatic glucose output.
• Biochemical consequences: severe fasting hypoglycaemia (since liver cannot release free glucose), accumulation
of glycogen in liver and kidney (hepatomegaly, renomegaly).
• Excess glucose-6-phosphate is shunted into glycolysis, producing lactic acidosis, and into the HMP
shunt/lipogenesis pathway, producing hyperlipidaemia (hypertriglyceridemia).
• Increased pyruvate/lactate also inhibits uric acid excretion by competing for the same renal transporter, causing
hyperuricemia and predisposing to gout.
• Clinical features: doll-like facies (fat cheeks), protuberant abdomen (hepatomegaly), growth retardation, bleeding
tendency (platelet dysfunction), and severe hypoglycaemic seizures if fasting is prolonged.
• Diagnosis: fasting hypoglycaemia with lactic acidosis, hyperlipidaemia, hyperuricemia; absent rise in blood
glucose after glucagon administration; liver biopsy showing enzyme deficiency/excess glycogen.
• Management: frequent feeding, continuous nocturnal gastric drip feeding or uncooked cornstarch to maintain
normoglycaemia and prevent metabolic complications.

Q4. Absorption of glucose and the transporters involved (GLUTs) (6 marks)

Reference values: GLUT1-GLUT5, SGLT1/SGLT2

• Dietary carbohydrates are digested to monosaccharides (glucose, galactose, fructose) in the intestinal lumen
before absorption across the intestinal mucosa.
Page 10
 Biochemistry Paper 1 — Short Notes
• Glucose and galactose are absorbed by secondary active transport via SGLT1 (Sodium-dependent Glucose
Transporter 1) on the luminal (brush border) membrane of enterocytes — co-transport with Na+ down its
electrochemical gradient (maintained by Na+/K+ ATPase on the basolateral membrane).
• Fructose is absorbed by facilitated diffusion via GLUT5 on the luminal membrane (energy-independent, does not
require Na+).
• All three monosaccharides exit the enterocyte into the portal blood via GLUT2 on the basolateral membrane.
• GLUT (Glucose Transporter) family — facilitative, Na+-independent transporters found in different tissues, each
with distinct Km and function:
• GLUT1: erythrocytes, brain (blood-brain barrier) — basal glucose uptake, low Km (high affinity).
• GLUT2: liver, pancreatic beta-cells, kidney, intestine — high Km (low affinity), allows glucose sensing/bidirectional
transport proportional to blood glucose.
• GLUT3: neurons — high affinity, ensures glucose supply to brain even at low glucose levels; GLUT4: skeletal
muscle & adipose tissue — insulin-dependent, translocates to membrane upon insulin stimulation (key to
postprandial glucose uptake).
• Clinical relevance: SGLT2 inhibitors (gliflozins) block renal glucose reabsorption, used as antidiabetic drugs causing
glucosuria; GLUT4 dysfunction contributes to insulin resistance in Type 2 Diabetes Mellitus.

Q5. Diagnostic criteria for diabetes mellitus and laboratory investigations (6 marks)

Reference values: FBS >=126 mg/dL | RBS >=200 mg/dL with symptoms | 2-hr OGTT >=200 mg/dL | HbA1c >=6.5%

• Diabetes Mellitus is diagnosed using any ONE of the following criteria (American Diabetes Association/WHO),
confirmed by repeat testing on a different day (unless unequivocal hyperglycaemia with classic symptoms):
• 1. Fasting Plasma Glucose (FPG) >=126 mg/dL (7.0 mmol/L) — fasting defined as no caloric intake for at least 8
hours.
• 2. 2-hour Plasma Glucose >=200 mg/dL (11.1 mmol/L) during an Oral Glucose Tolerance Test (OGTT) using a 75 g
anhydrous glucose load.
• 3. Random Plasma Glucose >=200 mg/dL (11.1 mmol/L) in a patient with classic symptoms of hyperglycaemia
(polyuria, polydipsia, polyphagia, unexplained weight loss) or hyperglycaemic crisis.
• 4. Glycated Haemoglobin (HbA1c) >=6.5%, reflecting average glycaemic control over the preceding 8-12 weeks.
• Prediabetes categories: Impaired Fasting Glucose (FPG 100-125 mg/dL), Impaired Glucose Tolerance (2-hr OGTT
140-199 mg/dL), HbA1c 5.7-6.4%.
• Laboratory investigations: fasting and postprandial blood glucose, OGTT, HbA1c, urine for glucose/ketones, C-
peptide (assesses residual insulin secretion, useful to differentiate Type 1 vs Type 2), fasting lipid profile
(dyslipidaemia commonly coexists), and autoantibodies (anti-GAD, anti-islet cell) in suspected Type 1 DM.
• Monitoring/complication screening: renal function tests, urine microalbumin, fundus examination (retinopathy),
nerve conduction studies (neuropathy) are performed periodically in diagnosed diabetics.

Q6. Lactose intolerance (6 marks)

• Lactose intolerance results from deficiency or absence of lactase (beta-galactosidase), the brush-border enzyme
that hydrolyses dietary lactose into glucose and galactose in the small intestine.
• Types: Primary (adult-type) hypolactasia — a genetically programmed decline in lactase activity after weaning,
most common worldwide, more prevalent in Asian and African populations; Congenital lactase deficiency — rare,
autosomal recessive, presents at birth; Secondary lactase deficiency — acquired due to intestinal mucosal
damage (e.g., gastroenteritis, coeliac disease, Crohn's disease), usually reversible.
• Pathophysiology: undigested lactose remains in the intestinal lumen, exerting an osmotic effect that draws water
into the lumen, causing osmotic diarrhoea.

Page 11
 Biochemistry Paper 1 — Short Notes
• Unabsorbed lactose is fermented by colonic bacteria producing short-chain fatty acids, hydrogen, methane, and
carbon dioxide gas, leading to bloating, flatulence, and abdominal cramps.
• Clinical features: diarrhoea, abdominal pain/bloating, flatulence, and borborygmi occurring after ingestion of milk
or dairy products.
• Diagnosis: Hydrogen breath test (raised breath hydrogen after lactose load, due to bacterial fermentation) is the
most reliable non-invasive test; Lactose tolerance test (blood glucose fails to rise >20 mg/dL after oral lactose);
stool pH (acidic, <5.5) and reducing substances positive; intestinal biopsy with lactase assay is confirmatory but
invasive.
• Management: dietary lactose restriction/avoidance, use of lactose-free or lactase-treated dairy products, and oral
lactase enzyme supplements taken with dairy meals.

Q7. Cori cycle and glucose-alanine cycle (6 marks)

• Both cycles are inter-organ metabolic pathways that transport carbon skeletons from muscle to liver, allowing
recycling of carbon for glucose synthesis and sparing muscle protein.
• Cori Cycle (Lactate cycle): during anaerobic/vigorous muscle activity, pyruvate is reduced to lactate by lactate
dehydrogenase (regenerating NAD+ for continued glycolysis).
• Lactate diffuses into blood and is taken up by the liver, where it is reoxidised to pyruvate and used for
gluconeogenesis, regenerating glucose which is released back into blood for uptake by muscle — completing the
cycle.
• Significance of Cori cycle: prevents lactic acid accumulation/acidosis in muscle, recycles carbon skeletons without
net loss, and shifts the metabolic (ATP) burden of gluconeogenesis from muscle to liver (gluconeogenesis is
energy-costly, requiring 6 ATP equivalents per glucose).
• Glucose-Alanine Cycle: during fasting or prolonged exercise, muscle protein is catabolised, and amino groups are
transferred to pyruvate by alanine aminotransferase (ALT), forming alanine.
• Alanine is transported to the liver, where ALT regenerates pyruvate (used for gluconeogenesis to form glucose,
released back to muscle) and transfers the amino group into the urea cycle for safe nitrogen disposal as urea.
• Significance of glucose-alanine cycle: safely transports nitrogen from muscle to liver in a non-toxic form (avoiding
ammonia toxicity), supports hepatic gluconeogenesis during fasting, and provides muscle a source of glucose
indirectly derived from its own protein breakdown.
• Both cycles exemplify inter-organ cooperation essential for maintaining blood glucose homeostasis during
fasting/exercise.

Page 12
 Biochemistry Paper 1 — Short Notes

Q8. Rapoport-Luebering shunt pathway and its significance (6 marks)

Reference values: 2,3-BPG normally present in RBCs at ~4-5 mmol/L, roughly equimolar with Hb

• The Rapoport-Luebering shunt is a bypass pathway of glycolysis found specifically in erythrocytes (RBCs), diverting
the intermediate 1,3-bisphosphoglycerate (1,3-BPG).
• Normally in glycolysis, 1,3-BPG is converted to 3-phosphoglycerate by phosphoglycerate kinase, generating ATP
via substrate-level phosphorylation.
• In the shunt, 1,3-BPG is instead converted to 2,3-bisphosphoglycerate (2,3-BPG) by the enzyme
bisphosphoglycerate mutase.
• 2,3-BPG is subsequently hydrolysed to 3-phosphoglycerate by bisphosphoglycerate phosphatase, re-entering the
main glycolytic pathway — but this route bypasses ATP generation at the phosphoglycerate kinase step, so
'sacrifices' one ATP per molecule shunted.
• Significance: 2,3-BPG binds specifically to the beta-chains of deoxyhaemoglobin (in the central cavity of the
tetramer), stabilizing the low-oxygen-affinity T (taut) state.
• This decreases haemoglobin's affinity for oxygen, shifting the oxygen dissociation curve to the RIGHT, thereby
facilitating oxygen unloading/release to tissues.
• 2,3-BPG levels rise physiologically in conditions of chronic hypoxia, high altitude, chronic anaemia, and chronic
lung disease — an adaptive mechanism enhancing tissue oxygen delivery despite reduced oxygen-carrying
capacity or availability.
• Clinical relevance: stored blood (banked blood) shows depletion of 2,3-BPG over time, temporarily impairing
oxygen delivery capacity after transfusion until levels are replenished in vivo; fetal haemoglobin (HbF) binds 2,3-
BPG poorly, giving it higher O2 affinity than maternal HbA, favouring placental oxygen transfer to the fetus.

Page 13
 Biochemistry Paper 1 — Short Notes

Q9. Reactions and regulation of Glycogenesis vs Glycogenolysis (6 marks)

• Glycogenesis (synthesis) and glycogenolysis (breakdown) are reciprocally regulated pathways maintaining glucose
homeostasis by storing/mobilising glycogen, mainly in liver and muscle.
• Glycogenesis steps: Glucose -> Glucose-6-phosphate (hexokinase/glucokinase) -> Glucose-1-phosphate
(phosphoglucomutase) -> UDP-glucose (UDPG pyrophosphorylase, using UTP) -> Glycogen chain elongation by
Glycogen synthase (rate-limiting enzyme, forms alpha-1,4 glycosidic bonds) -> Branching enzyme introduces
alpha-1,6 branch points.
• Glycogenolysis steps: Glycogen phosphorylase (rate-limiting, pyridoxal phosphate-dependent) cleaves alpha-1,4
bonds releasing Glucose-1-phosphate sequentially from non-reducing ends; Debranching enzyme
(glucosidase/transferase activity) removes alpha-1,6 branch points; Glucose-1-phosphate -> Glucose-6-phosphate
(phosphoglucomutase) -> free Glucose (Glucose-6-phosphatase — present only in liver/kidney, absent in muscle,
so muscle glycogen cannot directly raise blood glucose).

Page 14
 Biochemistry Paper 1 — Short Notes
• Hormonal regulation — Insulin (fed state): activates glycogen synthase (via dephosphorylation, protein
phosphatase-1) and inhibits glycogen phosphorylase, promoting glycogenesis.
• Glucagon (liver, fasting state) and Epinephrine (liver and muscle, stress/exercise): bind receptors, activate
adenylate cyclase -> raise cAMP -> activate Protein Kinase A -> phosphorylates and activates glycogen
phosphorylase kinase and glycogen phosphorylase (activation), while phosphorylating and inactivating glycogen
synthase — promoting glycogenolysis and inhibiting glycogenesis simultaneously.
• Allosteric regulation: high glucose-6-phosphate stimulates glycogen synthase; AMP allosterically activates muscle
phosphorylase (energy-deficient state signals breakdown); Calcium (released during muscle contraction) activates
phosphorylase kinase directly.
• This reciprocal control (via covalent phosphorylation/dephosphorylation) ensures glycogenesis and glycogenolysis
are never simultaneously active, preventing futile cycling.

Q10. Fructose metabolism pathway and the biochemical basis of Hereditary

Fructose Intolerance (Aldolase B deficiency) (6 marks)
• Dietary fructose (from sucrose, fruits, honey) is metabolised predominantly in the liver, via a pathway distinct
from and bypassing the rate-limiting, tightly-regulated step of glycolysis.
• Step 1: Fructokinase phosphorylates fructose to Fructose-1-phosphate (this enzyme has high affinity/Vmax and is
not subject to the regulatory control that phosphofructokinase exerts on glucose metabolism).
• Step 2: Aldolase B (fructose-1-phosphate aldolase, liver-specific isoform) cleaves fructose-1-phosphate into
Glyceraldehyde and Dihydroxyacetone phosphate (DHAP).
• These triose products are converted to glyceraldehyde-3-phosphate and enter glycolysis/gluconeogenesis,
allowing fructose to contribute to energy production or glucose synthesis.
• Hereditary Fructose Intolerance (HFI): autosomal recessive deficiency of Aldolase B, blocking the breakdown of
fructose-1-phosphate.

Page 15
 Biochemistry Paper 1 — Short Notes
• Pathophysiology: fructose-1-phosphate accumulates in the liver, trapping and depleting intracellular inorganic
phosphate — this inhibits glycogen phosphorylase (blocking glycogenolysis) and gluconeogenesis, producing
severe hypoglycaemia after fructose ingestion.
• Clinical features: appear on introduction of fruit/sucrose into diet (weaning) — vomiting, severe hypoglycaemia,
abdominal pain, hepatomegaly, jaundice, and if untreated, hepatic failure and renal tubular dysfunction; patients
characteristically develop an aversion to sweet foods.
• Management: strict lifelong exclusion of fructose and sucrose from the diet; diagnosis is by demonstrating
reducing substance in urine, hypoglycaemia following fructose challenge, and reduced Aldolase B activity on liver
biopsy or genetic testing.

Q11. Galactosemia — metabolic defects, clinical presentation (cataract formation),

and laboratory diagnosis (Mucic acid test) (6 marks)
• Galactosemia is an autosomal recessive disorder of galactose metabolism; galactose is derived mainly from
lactose (milk sugar) hydrolysis in the gut.
• Normal pathway (Leloir pathway): Galactose -> Galactose-1-phosphate (Galactokinase) -> reacts with UDP-
glucose via Galactose-1-phosphate uridyl transferase (GALT) to form UDP-galactose + Glucose-1-phosphate ->
UDP-galactose is epimerised back to UDP-glucose (UDP-galactose-4-epimerase), regenerating the cycle.
• Classic Galactosemia (Type I): deficiency of GALT (the most common and severe form) — blocks conversion of
galactose-1-phosphate, causing its toxic accumulation in liver, kidney, brain, and lens.
• Other types: Galactokinase deficiency (Type II, milder, causes cataract only) and Epimerase deficiency (Type III,
variable severity).
• Cataract formation: accumulated galactose is reduced by aldose reductase to galactitol (a sugar alcohol) in the
lens; galactitol cannot diffuse out and is osmotically active, drawing water into lens fibres, causing lens fibre
swelling, opacification, and cataract — often the earliest and most consistent sign, even in Galactokinase
deficiency alone.
• Clinical features (classic galactosemia): failure to thrive, vomiting, jaundice, hepatomegaly, hepatic failure,
hypoglycaemia, susceptibility to E. coli sepsis, and if untreated, intellectual disability and cataracts.

Page 16
 Biochemistry Paper 1 — Short Notes
• Laboratory diagnosis: reducing substance in urine (Benedict's test positive) that is glucose oxidase-negative
(specific test confirms it is not glucose); Mucic acid test — galactose, when oxidised with concentrated nitric acid,
forms mucic acid crystals (characteristic diagnostic test); definitive diagnosis by assay of RBC GALT enzyme activity
or genetic testing.
• Management: complete exclusion of galactose and lactose from diet (galactose-free formula) from birth; if
instituted early, cataracts and hepatic disease are reversible, though neurodevelopmental outcome may still be
affected.

Q12. Oral Glucose Tolerance Test (OGTT) — indications, precise clinical method,
and diagnostic interpretation (6 marks)
Reference values: 75 g glucose load; Normal 2-hr <140 mg/dL | IGT 140-199 mg/dL | Diabetic >=200 mg/dL

• OGTT assesses the body's ability to metabolise/dispose of an oral glucose load, used to diagnose diabetes
mellitus, impaired glucose tolerance, and gestational diabetes.
• Indications: borderline/equivocal fasting blood glucose values, screening for gestational diabetes (typically 24-28
weeks gestation), evaluation of impaired fasting glucose, family history of diabetes with normal fasting glucose
but clinical suspicion, and evaluating reactive hypoglycaemia.
• Patient preparation: normal unrestricted diet (>=150 g carbohydrate/day) for 3 days prior, overnight fast of 8-14
hours, test performed in the morning, patient should remain seated and not smoke during the test; certain drugs
(steroids, diuretics, oral contraceptives) and acute illness can affect results and should be noted.
• Procedure: a fasting venous blood sample is drawn first; the patient then ingests 75 g of anhydrous glucose
dissolved in 250-300 mL water within 5 minutes (in children, 1.75 g/kg body weight up to a maximum of 75 g);
further blood samples are drawn at 30, 60, 90, and 120 minutes (a simplified test uses only fasting and 2-hour
samples).

Page 17
 Biochemistry Paper 1 — Short Notes
• Interpretation (WHO/ADA criteria, 2-hour plasma glucose): Normal <140 mg/dL (7.8 mmol/L); Impaired Glucose
Tolerance (IGT) 140-199 mg/dL (7.8-11.0 mmol/L); Diabetes Mellitus >=200 mg/dL (11.1 mmol/L).
• For Gestational Diabetes (using 75 g OGTT, IADPSG criteria), diagnosis requires any one abnormal value: Fasting
>=92 mg/dL, 1-hour >=180 mg/dL, or 2-hour >=153 mg/dL.
• Clinical utility: a normal OGTT excludes diabetes; an abnormal test, especially with classic symptoms, confirms
diagnosis and guides early therapeutic intervention to prevent long-term vascular complications.

Q13. Polyol (sorbitol) pathway and its pathological importance in developing

chronic complications of Diabetes Mellitus (6 marks)
• The polyol pathway is an alternate route of glucose metabolism, normally contributing minimally to glucose
disposal (<3%) but becomes significant when intracellular glucose levels are markedly elevated (as in poorly
controlled diabetes).
• Step 1: Aldose reductase (NADPH-dependent) reduces glucose to sorbitol; this enzyme has a high Km for glucose,
so pathway flux is normally low but increases substantially in hyperglycaemia.
• Step 2: Sorbitol dehydrogenase (NAD+-dependent) oxidises sorbitol to fructose.
• This pathway operates in tissues that do NOT require insulin for glucose uptake (insulin-independent tissues),
including the lens, retina, peripheral nerves (Schwann cells), kidney, and blood vessel walls — precisely the sites
of classic diabetic microvascular complications.
• Pathological consequences: sorbitol, once formed, diffuses poorly across cell membranes and accumulates
intracellularly, causing osmotic stress, cellular swelling, and damage.
• Excess NADPH consumption by aldose reductase depletes NADPH available for glutathione regeneration,
impairing antioxidant defence and increasing oxidative stress (glutathione-dependent detoxification of reactive
oxygen species is compromised).
• Clinical correlations: lens — sorbitol accumulation causes osmotic swelling of lens fibres, contributing to diabetic
cataract; retina — contributes to diabetic retinopathy; peripheral nerves — sorbitol/fructose accumulation and
reduced myo-inositol contribute to diabetic peripheral neuropathy; kidney — contributes to diabetic
nephropathy.
• Aldose reductase inhibitors (e.g., epalrestat) have been studied as a therapeutic strategy to reduce flux through
this pathway and potentially slow progression of diabetic microvascular complications, though clinical efficacy
remains limited.

Page 18
 Biochemistry Paper 1 — Short Notes

Lipid Metabolism
Q1. Causes of fatty liver and the therapeutic role of lipotropic factors (6 marks)

• Fatty liver (hepatic steatosis) is the abnormal accumulation of triacylglycerol (TAG) within hepatocytes, occurring
when TAG synthesis/uptake exceeds its export as VLDL or its oxidation.
• Causes — Excess fatty acid delivery to liver: high-fat diet, uncontrolled diabetes mellitus (increased lipolysis),
starvation/fasting (mobilisation of adipose fat), chronic alcoholism (major cause).
• Causes — Impaired VLDL synthesis/secretion: deficiency of apolipoprotein B synthesis, or of lipotropic factors
needed for phospholipid (lecithin) synthesis required to package TAG into VLDL.
• Causes — Increased hepatic TAG synthesis: chronic alcohol intake increases NADH/NAD+ ratio, favouring fatty
acid synthesis and inhibiting beta-oxidation and TCA cycle activity, plus acetaldehyde-induced hepatocyte
damage.
• Causes — Toxins/drugs: carbon tetrachloride, certain chemotherapeutic agents, and protein-calorie malnutrition
(Kwashiorkor) impairing apolipoprotein synthesis.
• Lipotropic factors are substances that prevent or reduce fat accumulation in the liver by promoting phospholipid
synthesis (needed for VLDL formation) or fat oxidation.
• Important lipotropic factors: Choline (component of lecithin/phosphatidylcholine, essential for VLDL assembly),
Methionine (methyl donor for choline synthesis via SAMe), Betaine, Vitamin B12 and Folate (needed for
methionine regeneration from homocysteine), and Inositol.
• Therapeutic role: adequate dietary protein (methionine-rich) and lipotropic supplementation support VLDL export
of TAG from liver, helping prevent/treat fatty liver of malnutrition; in alcoholic and metabolic fatty liver disease,
the mainstay remains addressing the underlying cause (alcohol cessation, glycaemic control, weight reduction)
alongside adequate nutrition.

Q2. Eicosanoids — actions, uses, and the mechanism of Aspirin as an antiplatelet

drug (6 marks)
• Eicosanoids are 20-carbon signalling molecules derived from polyunsaturated fatty acids, chiefly arachidonic acid
(released from membrane phospholipids by phospholipase A2), including prostaglandins (PG), thromboxanes (TX),
leukotrienes (LT), and prostacyclins (PGI2).
• Cyclooxygenase (COX) pathway produces prostaglandins, thromboxanes, and prostacyclin; Lipoxygenase pathway
produces leukotrienes.
• Actions of Prostaglandins: PGE2 causes vasodilation, uterine contraction, fever (pyrogenic), pain sensitisation, and
cytoprotection of gastric mucosa (inhibits acid secretion, stimulates mucus).
• Actions of Thromboxane A2 (TXA2, from platelets): potent vasoconstrictor and promoter of platelet aggregation,
important in haemostasis and thrombosis.
• Actions of Prostacyclin (PGI2, from vascular endothelium): vasodilator and inhibitor of platelet aggregation —
physiologically opposes TXA2, maintaining vascular homeostasis.
• Actions of Leukotrienes: mediators of inflammation and allergic reactions (bronchoconstriction, chemotaxis of
leukocytes, increased vascular permeability) — important in asthma and anaphylaxis.
• Clinical uses of eicosanoid-related drugs: PGE analogues (misoprostol) for peptic ulcer protection/labour
induction; PGF2alpha for abortion; leukotriene receptor antagonists (montelukast) in asthma.
• Aspirin mechanism: irreversibly acetylates a serine residue on cyclooxygenase (COX-1), permanently inactivating
the enzyme (suicide/mechanism-based inhibition) in platelets, which — being anucleate — cannot synthesise new
COX enzyme for their ~7-10 day lifespan, resulting in sustained inhibition of TXA2 synthesis and a durable

Page 19
 Biochemistry Paper 1 — Short Notes
antiplatelet effect at low doses; endothelial cells, having nuclei, can resynthesise COX and restore PGI2
production, tilting the balance towards reduced platelet aggregation.

Q3. Clinical significance of phospholipids (6 marks)

• Phospholipids are amphipathic lipids (a polar/hydrophilic head and non-polar/hydrophobic fatty acid tails) that
serve as major structural and functional components of all biological membranes.
• Membrane structure: form the phospholipid bilayer of all cell membranes, providing selective permeability,
fluidity, and a matrix for embedded membrane proteins.
• Lipoprotein structure: phospholipids form the outer amphipathic monolayer of plasma lipoproteins
(chylomicrons, VLDL, LDL, HDL), allowing transport of hydrophobic lipids (TAG, cholesteryl esters) in the aqueous
plasma.
• Lung surfactant: dipalmitoyl phosphatidylcholine (lecithin) is the major component of pulmonary surfactant,
reducing alveolar surface tension and preventing alveolar collapse; deficiency causes Respiratory Distress
Syndrome in preterm neonates.
• Bile: phosphatidylcholine (lecithin) helps solubilise cholesterol in bile, maintaining it in micellar form; an altered
bile cholesterol:phospholipid:bile salt ratio (Admirand's triangle) predisposes to cholesterol gallstone formation.
• Second messenger signalling: phosphatidylinositol-4,5-bisphosphate (PIP2) is cleaved by phospholipase C into two
important second messengers — inositol trisphosphate (IP3, releases intracellular Ca2+) and diacylglycerol (DAG,
activates protein kinase C) — central to hormone/growth factor signal transduction.
• Blood coagulation: platelet phospholipids (platelet factor 3) provide a surface for assembly of clotting factor
complexes essential for the coagulation cascade.
• Clinical disorders: sphingomyelin accumulation in Niemann-Pick disease (sphingomyelinase deficiency); cardiolipin
is used as antigen in the VDRL test for syphilis; lecithin/sphingomyelin (L/S) ratio in amniotic fluid assesses fetal
lung maturity.

Q4. Digestion and absorption of lipids (6 marks)

• Lipid digestion begins minimally in the mouth (lingual lipase) and stomach (gastric lipase acting on short/medium
chain triglycerides), aided by mechanical emulsification via gastric peristalsis, but the bulk of digestion occurs in
the duodenum.
• Bile salts (synthesised in liver, stored/concentrated in gallbladder, released in response to cholecystokinin)
emulsify large fat globules into smaller droplets, increasing surface area for enzyme action.
• Pancreatic lipase (with colipase, which anchors the enzyme at the oil-water interface and prevents bile-salt
inhibition) hydrolyses triacylglycerol at the sn-1 and sn-3 positions, yielding 2-monoacylglycerol and free fatty
acids.
• Other pancreatic enzymes: Cholesterol esterase hydrolyses cholesteryl esters to free cholesterol; Phospholipase
A2 (activated from pro-enzyme by trypsin) hydrolyses phospholipids to lysophospholipids and free fatty acids.
• These digestion products combine with bile salts to form mixed micelles, which solubilise the lipid products and
transport them to the brush border of enterocytes for absorption (bile salts themselves are absorbed later, in the
terminal ileum, via enterohepatic circulation).
• Within enterocytes, 2-monoacylglycerol and free fatty acids are re-esterified to triacylglycerol (via the
monoacylglycerol pathway, using acyl-CoA synthetase and acyltransferases in smooth endoplasmic reticulum).
• Resynthesised TAG, cholesteryl esters, and phospholipids are packaged with apolipoprotein B-48 into
chylomicrons, which are secreted by exocytosis into intestinal lymphatics (lacteals), bypassing the portal
circulation, and reach systemic blood via the thoracic duct.
• Short and medium-chain fatty acids (<12 carbons) are exceptions: being more water-soluble, they are absorbed
directly into the portal blood bound to albumin, without requiring micelle formation or chylomicron packaging.

Page 20
 Biochemistry Paper 1 — Short Notes

Q5. Name the ketone bodies. Explain why the liver cannot utilize ketone bodies as
an energy source (6 marks)
• The three ketone bodies are Acetoacetate, beta-Hydroxybutyrate, and Acetone (a minor, spontaneously formed
decarboxylation product of acetoacetate, exhaled via lungs giving characteristic breath odour).
• Ketone bodies are synthesised exclusively in the liver mitochondria (ketogenesis), from excess acetyl-CoA
generated during high rates of fatty acid beta-oxidation (e.g., prolonged fasting, starvation, uncontrolled diabetes
mellitus).
• Ketogenesis pathway: 2 Acetyl-CoA -> Acetoacetyl-CoA (thiolase) -> combines with a third Acetyl-CoA via HMG-
CoA synthase (rate-limiting enzyme) to form HMG-CoA -> cleaved by HMG-CoA lyase to Acetoacetate (+ Acetyl-
CoA) -> Acetoacetate is reduced to beta-hydroxybutyrate (beta-hydroxybutyrate dehydrogenase) or
spontaneously decarboxylates to Acetone.
• Ketone bodies are water-soluble, can cross the blood-brain barrier, and serve as an important alternative fuel for
extrahepatic tissues (skeletal muscle, cardiac muscle, renal cortex, and importantly the brain during prolonged
starvation) when glucose is scarce.
• Utilisation in peripheral tissues requires the enzyme Thiophorase (succinyl-CoA: acetoacetate CoA-transferase),
which transfers CoA from succinyl-CoA to acetoacetate, forming acetoacetyl-CoA, which is then cleaved to 2
acetyl-CoA molecules for entry into the TCA cycle.
• The liver characteristically LACKS thiophorase (this enzyme is absent specifically in hepatic mitochondria), so
although the liver is the sole site of ketone body production, it cannot itself utilise the ketone bodies it produces.
• This arrangement is teleologically purposeful: it ensures ketone bodies produced in liver are exported for use by
peripheral tissues (particularly sparing glucose for the brain and RBCs during fasting), rather than being consumed
locally by the very organ producing them.
• Clinical relevance: excessive, unregulated ketogenesis (as in uncontrolled Type 1 Diabetes Mellitus) overwhelms
peripheral utilisation capacity, causing ketonaemia/ketonuria and metabolic (high anion gap) acidosis — Diabetic
Ketoacidosis.

Page 21
 Biochemistry Paper 1 — Short Notes

Q6. Metabolism, synthesis, and utilization of ketone bodies during diabetic

ketoacidosis (DKA) (6 marks)
Reference values: DKA: blood glucose usually >250 mg/dL, arterial pH <7.3, serum bicarbonate <18 mEq/L, positive serum/urine
ketones

• Diabetic Ketoacidosis (DKA) is an acute, life-threatening metabolic complication of (usually Type 1) diabetes
mellitus, arising from absolute or severe relative insulin deficiency combined with excess counter-regulatory
hormones (glucagon, catecholamines, cortisol).
• Insulin deficiency + high glucagon activates hormone-sensitive lipase in adipose tissue, causing massive lipolysis
and release of free fatty acids into circulation.
• Free fatty acids are taken up by the liver and undergo beta-oxidation; the resulting surge of acetyl-CoA exceeds
the oxidative capacity of the TCA cycle (whose intermediates, especially oxaloacetate, are diverted toward
gluconeogenesis under glucagon's influence).
• Excess acetyl-CoA is therefore shunted into ketogenesis: HMG-CoA synthase (upregulated/activated in this state)
drives increased formation of Acetoacetate and beta-hydroxybutyrate far beyond the rate of peripheral
utilisation.
• Ketone bodies are moderately strong acids; their massive overproduction overwhelms the bicarbonate buffering
system, producing a high anion gap metabolic acidosis.
• Concurrently, severe hyperglycaemia (from unchecked gluconeogenesis and glycogenolysis, and impaired
peripheral glucose uptake) causes osmotic diuresis, leading to dehydration and electrolyte derangement (notably
total body potassium depletion despite normal/high serum potassium initially).
• Clinical features: polyuria, polydipsia, nausea/vomiting, abdominal pain, Kussmaul breathing (deep, rapid
respiration compensating for acidosis), fruity (acetone) breath odour, altered sensorium progressing to coma if
untreated.

Page 22
 Biochemistry Paper 1 — Short Notes
• Management principles: intravenous fluid resuscitation, insulin therapy (halts lipolysis/ketogenesis and promotes
glucose utilisation), careful potassium replacement, and correction of the underlying precipitating cause
(infection, missed insulin doses).

Q7. Chylomicron metabolism and the clinical significance of type I

hyperlipoproteinemia (creamy serum) (6 marks)
• Chylomicrons are the largest, least dense lipoproteins, formed in intestinal mucosal cells (enterocytes) to
transport dietary (exogenous) triacylglycerol and cholesterol.
• Formation: after lipid absorption, re-esterified TAG and cholesteryl esters are packaged with apolipoprotein B-48,
phospholipids, and cholesterol into nascent chylomicrons, secreted by exocytosis into intestinal lacteals
(lymphatics), bypassing the portal vein, reaching systemic circulation via the thoracic duct.
• Maturation: in plasma, nascent chylomicrons acquire apolipoprotein C-II and apolipoprotein E from circulating
HDL, becoming mature chylomicrons.
• Peripheral processing: apo C-II activates Lipoprotein Lipase (LPL), an enzyme anchored to capillary endothelium of
adipose tissue, skeletal/cardiac muscle, and lactating mammary gland — LPL hydrolyses the core TAG, releasing
free fatty acids and glycerol for uptake and use/storage by these tissues.
• As TAG content diminishes, the particle shrinks into a cholesterol-ester-enriched Chylomicron Remnant, which
transfers excess surface components (phospholipid, apo C-II) back to HDL.
• Hepatic clearance: chylomicron remnants are recognised via apolipoprotein E and cleared from circulation by
hepatic receptors (apo E receptor/LDL-receptor-related protein, LRP), delivering dietary cholesterol to the liver.
• Type I Hyperlipoproteinemia (Familial Chylomicronemia Syndrome): rare autosomal recessive disorder caused by
deficiency of Lipoprotein Lipase or its cofactor apolipoprotein C-II, preventing chylomicron clearance from
plasma.
• Clinical significance: massive fasting hypertriglyceridaemia with chylomicrons persisting in fasting plasma,
producing a characteristic creamy supernatant layer on standing serum (chylomicron test); clinical features

Page 23
 Biochemistry Paper 1 — Short Notes
include eruptive cutaneous xanthomas, hepatosplenomegaly, lipaemia retinalis (creamy retinal vessels on
fundoscopy), and recurrent, potentially severe acute pancreatitis; managed with strict dietary fat restriction.

Q8. Composition of lung surfactant and the biochemical basis/diagnostic

relevance of the L/S ratio in Respiratory Distress Syndrome (RDS) (6 marks)
Reference values: L/S ratio >=2:1 indicates fetal lung maturity; <1.5:1 indicates high RDS risk

• Pulmonary surfactant is a lipoprotein complex synthesised and secreted by Type II pneumocytes of the alveolar
epithelium, essential for normal lung mechanics.
• Composition: approximately 90% lipid and 10% protein; the major lipid component is Dipalmitoyl
Phosphatidylcholine (DPPC, also called dipalmitoyl lecithin), comprising roughly 50% of surfactant lipid, along with
other phospholipids (phosphatidylglycerol, phosphatidylinositol) and cholesterol.
• Surfactant proteins (SP-A, SP-B, SP-C, SP-D) assist in surfactant packaging, secretion, recycling, and innate immune
defence within the alveolus.
• Function: surfactant reduces alveolar surface tension (by disrupting the cohesive forces between water molecules
at the air-liquid interface), particularly at end-expiration when alveolar radius is smallest (per Laplace's law,
collapsing pressure is inversely proportional to radius) — preventing alveolar collapse (atelectasis) and reducing
the work of breathing.
• Surfactant synthesis matures late in gestation, typically becoming adequate around 34-36 weeks; sphingomyelin,
produced earlier and at a relatively constant rate, is used as a stable reference for comparison.
• The Lecithin/Sphingomyelin (L/S) ratio is measured in amniotic fluid (obtained by amniocentesis) to assess fetal
lung maturity before elective preterm delivery or in pregnancies at risk of preterm labour.
• Interpretation: L/S ratio >=2:1 indicates mature lungs with low risk of RDS; ratio <1.5:1 indicates immature lungs
with high risk of RDS; an intermediate ratio (1.5-1.9:1) carries indeterminate risk. Presence of
phosphatidylglycerol further supports lung maturity.
• Clinical significance: Respiratory Distress Syndrome (Hyaline Membrane Disease) occurs due to surfactant
deficiency in preterm neonates, causing progressive atelectasis, hypoxia, and respiratory failure; antenatal
Page 24
 Biochemistry Paper 1 — Short Notes
corticosteroids accelerate fetal surfactant production, and exogenous surfactant replacement therapy is used
postnatally to treat/prevent RDS.

Page 25
 Biochemistry Paper 1 — Short Notes

Heme, Proteins & Integration of Metabolism

Q1. Sickle cell anaemia — etiopathogenesis and diagnosis (6 marks)

Reference values: HbS: substitution of Glutamate -> Valine at position 6 of beta-globin chain

• Sickle cell anaemia is an autosomal recessive haemoglobinopathy caused by a single point mutation (GAG -> GTG)
in the beta-globin gene, resulting in substitution of hydrophilic Glutamate by hydrophobic Valine at position 6 of
the beta-globin chain, producing abnormal Haemoglobin S (HbS) instead of normal HbA.
• Etiopathogenesis: the substituted valine creates a hydrophobic patch on the surface of the deoxygenated beta-
chain that fits into a complementary hydrophobic pocket on an adjacent deoxyhaemoglobin molecule.
• Under low oxygen tension (deoxygenated state), HbS molecules polymerise into long, rigid fibres, distorting the
red blood cell into a characteristic sickle (crescent) shape.
• Sickled cells are rigid and fragile, causing: (a) increased haemolysis (extravascular, in spleen) leading to chronic
haemolytic anaemia, and (b) vaso-occlusion — sickled cells obstruct microcirculation, causing tissue ischaemia,
infarction, and severe pain crises.
• Repeated sickling-unsickling cycles damage the RBC membrane, eventually causing irreversibly sickled cells;
splenic infarction over time leads to functional asplenia (autosplenectomy), increasing susceptibility to
encapsulated organism infections.
• Heterozygotes (Sickle cell trait, HbAS) are generally asymptomatic but confer relative protection against
Plasmodium falciparum malaria, explaining the high gene frequency in malaria-endemic regions.
• Diagnosis: Peripheral blood smear shows sickle-shaped RBCs, target cells, Howell-Jolly bodies (from
hyposplenism); Sickling test (metabisulfite reduction test induces sickling in vitro); Solubility test (Sickledex — HbS
is insoluble in reducing buffer, causing turbidity); Haemoglobin electrophoresis (definitive test, shows HbS band
with characteristic migration distinct from HbA) and HPLC.
• Clinical features: chronic haemolytic anaemia, recurrent painful vaso-occlusive crises, dactylitis, splenic
sequestration, increased infection risk, and long-term organ damage (renal, pulmonary, stroke risk).

Q2. Anaplerotic role of the TCA cycle (6 marks)

• The TCA (Krebs) cycle is described as 'amphibolic' because, in addition to its catabolic (oxidative) role in
generating energy, its intermediates are continuously withdrawn for biosynthetic purposes — a process that
would deplete the cycle unless intermediates are replenished.
• Anaplerosis (from Greek, 'to fill up') refers to reactions that replenish TCA cycle intermediates, maintaining
adequate concentrations for the cycle to continue functioning.
• Key anaplerotic reaction: Pyruvate Carboxylase (biotin-dependent, mitochondrial) converts pyruvate to
oxaloacetate — the most important anaplerotic reaction, particularly active in liver and kidney, and essential for
gluconeogenesis.
• Amino acid catabolism contributes several anaplerotic intermediates: glutamate/glutamine -> alpha-
ketoglutarate (via glutamate dehydrogenase/transamination); aspartate -> oxaloacetate (transamination); valine,
isoleucine, methionine -> succinyl-CoA (via propionyl-CoA pathway); phenylalanine/tyrosine -> fumarate.
• Odd-chain fatty acid oxidation produces propionyl-CoA, which is converted (via methylmalonyl-CoA, vitamin B12-
dependent) to succinyl-CoA, another anaplerotic entry point.
• Cataplerosis (opposite process) refers to removal of TCA intermediates for biosynthesis — e.g., oxaloacetate for
gluconeogenesis and aspartate synthesis, alpha-ketoglutarate for glutamate/glutamine and other amino acid
synthesis, citrate exported to cytosol for fatty acid/cholesterol synthesis, succinyl-CoA for haem synthesis.

Page 26
 Biochemistry Paper 1 — Short Notes
• Anaplerosis and cataplerosis must remain balanced for the TCA cycle to continue functioning both as an energy-
generating pathway and as a biosynthetic hub — this dual role (energy production plus provision of biosynthetic
precursors) is the basis for calling it an 'amphibolic' pathway.
• Clinical relevance: inadequate anaplerosis (e.g., in severe fasting/starvation when amino acid and propionate
sources are limited) can impair TCA cycle flux and hepatic energy metabolism/gluconeogenesis.

Q3. Metabolic pathway integration during fasting (6 marks)

• Fasting triggers a coordinated, phase-wise metabolic response aimed at maintaining blood glucose (especially for
glucose-dependent tissues like brain and RBCs) while conserving body protein.
• Early fasting (first few hours, post-absorptive): falling insulin and rising glucagon promote hepatic glycogenolysis,
the primary and most rapid source of blood glucose.
• As liver glycogen stores (limited to about 24 hours) begin to deplete, gluconeogenesis is progressively activated,
using lactate (from Cori cycle), glycerol (from adipose lipolysis), and glucogenic amino acids (notably alanine, from
glucose-alanine cycle) as substrates.
• Simultaneously, glucagon and catecholamines activate hormone-sensitive lipase in adipose tissue, increasing
lipolysis and release of free fatty acids into the circulation.
• Muscle and most other tissues (except brain and RBCs) increasingly shift to using free fatty acids as their primary
fuel, sparing glucose (glucose-fatty acid or 'Randle' cycle).
• Prolonged fasting/starvation (beyond ~2-3 days): the liver increasingly converts fatty acids to ketone bodies
(ketogenesis), which become an important alternative fuel; after 1-3 weeks, the brain adapts to use ketone
bodies for up to 60-70% of its energy needs, dramatically reducing obligatory glucose requirement and thereby
sparing muscle protein from excessive breakdown.
• Protein sparing: reduced need for glucogenic amino acids (due to ketone body utilisation by brain and fatty acid
utilisation by muscle) slows the rate of muscle protein catabolism as starvation progresses, a critical adaptive
mechanism for survival.
• Hormonal orchestration: low insulin/high glucagon ratio is the central driver throughout, complemented by
cortisol (promotes proteolysis/gluconeogenesis) and growth hormone/catecholamines (promote lipolysis) —
collectively integrating carbohydrate, lipid, and protein metabolism to maintain homeostasis during nutrient
deprivation.

Q4. Collagen — types and clinical significance (6 marks)

• Collagen is the most abundant protein in the human body, providing tensile strength to connective tissue; its
unique triple helical structure is composed of three polypeptide (alpha) chains, characterised by a repeating Gly-
X-Y sequence (X and Y often proline and hydroxyproline).
• Post-translational modifications essential for stability: hydroxylation of proline and lysine residues (requires
Vitamin C, molecular oxygen, alpha-ketoglutarate, and Fe2+ as cofactors), and formation of covalent cross-links
via lysyl oxidase (a copper-dependent enzyme).
• Type I collagen: most abundant type; found in skin, bone, tendon, ligaments, and cornea; mutations cause
Osteogenesis Imperfecta ('brittle bone disease').
• Type II collagen: found in cartilage and vitreous humour of the eye; mutations associated with chondrodysplasias.
• Type III collagen: found in skin, blood vessels, and internal organs (reticular fibres); associated with Vascular (Type
IV) Ehlers-Danlos syndrome when defective.
• Type IV collagen: forms a non-fibrillar meshwork in basement membranes; mutations cause Alport syndrome
(hereditary nephritis with hearing loss and eye defects) due to defective glomerular basement membrane.
• Other clinically important types: Type V (associated with placenta, and with classic Ehlers-Danlos syndrome), Type
IX (interacts with Type II in cartilage).

Page 27
 Biochemistry Paper 1 — Short Notes
• Clinical significance of collagen disorders: Vitamin C deficiency (Scurvy) impairs proline/lysine hydroxylation,
producing weak, unstable collagen causing bleeding gums, poor wound healing, and perifollicular haemorrhages;
Ehlers-Danlos syndromes (hyperextensible skin, joint hypermobility) and Osteogenesis Imperfecta result from
structural collagen gene defects; Menkes disease (copper deficiency) impairs lysyl oxidase activity, weakening
collagen cross-linking.

Q5. Clinically significant peptides (6 marks)

• Peptides are short chains of amino acids joined by peptide bonds; several endogenous and exogenous peptides
have important clinical/diagnostic/therapeutic significance.
• Glutathione (gamma-glutamyl-cysteinyl-glycine): a tripeptide with an unusual gamma-peptide bond; functions as
the major intracellular antioxidant, protecting cells from oxidative damage (via glutathione peroxidase) and
participating in detoxification (conjugation with xenobiotics via glutathione-S-transferase).
• Oxytocin and Vasopressin (ADH): nonapeptides synthesised in the hypothalamus; oxytocin stimulates uterine
contraction and milk ejection; vasopressin regulates water reabsorption in renal collecting ducts and causes
vasoconstriction.
• Insulin and C-peptide: insulin is a peptide hormone (two chains, A and B, linked by disulfide bonds) formed from
proinsulin by cleavage of C-peptide; C-peptide measurement is clinically useful to assess endogenous insulin
secretion (unaffected by exogenous insulin therapy), helping distinguish Type 1 from Type 2 diabetes and
diagnosing insulinoma/factitious hypoglycaemia.
• Natriuretic peptides (ANP, BNP): released from cardiac atria/ventricles in response to stretch/volume overload;
BNP (and NT-proBNP) is a key biomarker used in diagnosing and monitoring congestive heart failure.
• Bradykinin and Angiotensin II: bradykinin is a potent vasodilator involved in inflammation and pain; Angiotensin II
(formed from angiotensinogen via renin and ACE) is a potent vasoconstrictor central to blood pressure regulation
(target of ACE inhibitors/ARBs).
• Substance P: an important neuropeptide involved in pain transmission and neurogenic inflammation.
• Therapeutic/synthetic peptides: Desmopressin (vasopressin analogue, used in diabetes insipidus and
haemophilia), Octreotide (somatostatin analogue), Glucagon-like peptide-1 (GLP-1) agonists (used in Type 2
Diabetes/obesity management) illustrate the growing clinical application of peptide-based therapeutics.

Q6. Oxygen dissociation curve (ODC) and the physiological causes shifting it to
the right (6 marks)
Reference values: P50 (normal) = 26-27 mmHg

• The Oxygen Dissociation Curve is a sigmoid (S-shaped) graph plotting percentage saturation of haemoglobin with
oxygen against the partial pressure of oxygen (pO2), reflecting cooperative binding of O2 to the four haem sites of
haemoglobin.
• The sigmoid shape arises because binding of the first oxygen molecule increases affinity for subsequent molecules
(positive cooperativity, T-to-R state transition), described by the Hill equation.
• P50 is the pO2 at which haemoglobin is 50% saturated; it is a standard index of haemoglobin's oxygen affinity —
normal P50 is approximately 26-27 mmHg.
• A rightward shift of the curve indicates DECREASED affinity of haemoglobin for oxygen (higher P50), meaning
haemoglobin releases oxygen more readily to tissues at any given pO2 — physiologically advantageous in tissues
with high metabolic demand.
• Causes of right shift (the 'Bohr effect' and related factors): Increased H+ concentration/decreased pH (acidosis) —
as occurs in actively metabolising, CO2-producing tissues; Increased pCO2 (carbon dioxide directly and via
carbamino compound formation, and via bicarbonate-mediated pH fall).
• Increased temperature — as in exercising muscle or febrile states; Increased 2,3-Bisphosphoglycerate (2,3-BPG)
— produced via the Rapoport-Luebering shunt, rises in chronic hypoxia, high altitude, and chronic anaemia.

Page 28
 Biochemistry Paper 1 — Short Notes
• A leftward shift (increased O2 affinity, lower P50) occurs with opposite changes: decreased
H+/CO2/temperature/2,3-BPG, and also with fetal haemoglobin (HbF, which binds 2,3-BPG poorly),
carboxyhaemoglobin, and methaemoglobin.
• Clinical/physiological significance: the right shift in actively respiring tissues facilitates oxygen unloading exactly
where it is needed most, while in the lungs (lower temperature, lower CO2/H+ locally) the curve favours oxygen
loading — this dynamic behaviour optimises oxygen delivery matched to tissue demand.

Q7. Methemoglobinemia — types and diagnosis (6 marks)

Reference values: Normal MetHb <1% of total haemoglobin; cyanosis appears when MetHb >10%; levels >50-60% can be fatal

• Methemoglobinemia is a condition in which haemoglobin's haem iron is oxidised from the ferrous (Fe2+) to the
ferric (Fe3+) state, forming methaemoglobin (MetHb), which is incapable of binding oxygen.
• Normally, a small amount of methaemoglobin (<1%) forms continuously due to spontaneous auto-oxidation but is
promptly reduced back to functional Hb by protective enzyme systems, chiefly NADH-cytochrome b5 reductase
(methaemoglobin reductase, responsible for ~95-99% of reduction) and to a lesser extent the NADPH-dependent
pathway (requiring G6PD and methylene blue as an artificial electron carrier for therapeutic reduction).
• Congenital (Hereditary) Methemoglobinemia: Type I — deficiency of NADH-cytochrome b5 reductase restricted to
red cells (milder, presents with cyanosis but is otherwise generally well-tolerated); Type II — generalised enzyme
deficiency (including in other tissues), associated with severe neurological impairment.
• Haemoglobin M disease: rare autosomal dominant mutations in globin genes that stabilise the ferric state of
haem, causing congenital methemoglobinemia resistant to standard reductive therapy.
• Acquired (Toxic) Methemoglobinemia: far more common; caused by exposure to oxidising agents/drugs such as
nitrites/nitrates (well water contamination, especially in infants), dapsone, sulfonamides, local anaesthetics
(benzocaine, prilocaine), and aniline dyes — these overwhelm the physiological reductive capacity.

Page 29
 Biochemistry Paper 1 — Short Notes
• Clinical features: cyanosis disproportionate to the degree of hypoxaemia (classic 'chocolate-brown' colour of
blood), which characteristically does NOT improve with supplemental oxygen; headache, fatigue, dyspnoea;
severe cases (>50-60% MetHb) can cause seizures, coma, and death.
• Diagnosis: pulse oximetry is unreliable (often shows falsely intermediate SpO2 around 85%); definitive diagnosis
by co-oximetry (measures MetHb directly), and characteristic 'chocolate-brown' colour of blood that does not
turn red on exposure to air/oxygen (unlike deoxygenated blood).
• Management: Methylene blue (reduced by NADPH-methaemoglobin reductase using NADPH from G6PD
pathway) is the standard treatment — but is contraindicated/ineffective in G6PD deficiency, where ascorbic acid
or exchange transfusion may be needed instead.

Q8. Risk factors of cardiovascular disease, cardiac biomarkers, and preventive

lipid screening methods (6 marks)
Reference values: Desirable total cholesterol <200 mg/dL | LDL-C <100 mg/dL | HDL-C >=40 mg/dL (men), >=50 mg/dL (women) |
Triglycerides <150 mg/dL

• Cardiovascular disease (CVD) risk factors are classified as non-modifiable and modifiable, and their identification
underpins preventive strategy.
• Non-modifiable risk factors: increasing age, male sex (until menopause, after which female risk approaches male
levels), family history/genetic predisposition (e.g., familial hypercholesterolaemia).
• Modifiable risk factors: dyslipidaemia (raised LDL-cholesterol, low HDL-cholesterol, raised triglycerides),
hypertension, diabetes mellitus/insulin resistance, smoking, obesity (especially central/visceral adiposity),
sedentary lifestyle, and unhealthy diet.
• Emerging/novel risk markers: raised homocysteine (homocystinuria increases atherosclerosis risk), elevated
Lipoprotein(a) [Lp(a)], raised C-reactive protein (hs-CRP, a marker of vascular inflammation), and raised
fibrinogen.
• Cardiac biomarkers (for diagnosis of acute myocardial infarction and risk stratification): Troponin I/T (cardiac-
specific, most sensitive and specific marker, rises within 3-6 hours, remains elevated for 7-10 days); CK-MB (rises
within 4-6 hours, peaks at 24 hours, normalises by 48-72 hours, useful for detecting reinfarction); Myoglobin
(earliest to rise, but non-specific); LDH1 (historically used, now largely superseded).
• BNP/NT-proBNP is used as a biomarker of ventricular wall stress/heart failure rather than acute ischaemia
specifically.
• Preventive lipid screening: fasting lipid profile (Total cholesterol, LDL-C, HDL-C, Triglycerides) is recommended
periodically in adults, with earlier/more frequent screening in those with diabetes, hypertension, obesity, or
family history of premature CVD; desirable levels: Total cholesterol <200 mg/dL, LDL-C <100 mg/dL (lower targets
in high-risk patients), HDL-C >=40 mg/dL (men)/>=50 mg/dL (women), Triglycerides <150 mg/dL.
• Preventive strategy integrates lifestyle modification (diet, exercise, smoking cessation, weight control) with
pharmacotherapy (statins, antihypertensives, antidiabetic agents) guided by overall calculated cardiovascular risk
scores.

Q9. Structural features and biological functions of cell organelles: Mitochondria

and Nucleus (6 marks)
• Mitochondria — Structure: double membrane-bound organelle; smooth, porin-containing outer membrane
(freely permeable to small molecules); highly folded inner membrane (cristae, increasing surface area) that is
impermeable to most ions/molecules, containing the ETC complexes and ATP synthase.
• Mitochondrial matrix contains: TCA cycle enzymes, beta-oxidation enzymes, portions of the urea cycle, pyruvate
dehydrogenase complex, circular double-stranded mitochondrial DNA (mtDNA, inherited maternally, encodes 13
ETC proteins plus rRNA/tRNA), and 70S (prokaryote-like) ribosomes.
• Mitochondrial functions: principal site of ATP generation via oxidative phosphorylation ('powerhouse of the cell');
site of TCA cycle, fatty acid beta-oxidation, part of urea cycle and haem synthesis; regulates apoptosis via
Page 30
 Biochemistry Paper 1 — Short Notes
cytochrome c release; involved in calcium homeostasis and generates heat (via uncoupling proteins in brown
adipose tissue, e.g., thermogenin/UCP1).
• Nucleus — Structure: largest organelle, bound by a double membrane (nuclear envelope) continuous with the
endoplasmic reticulum, perforated by nuclear pore complexes that regulate selective bidirectional transport of
molecules (RNA out, proteins/nucleotides in).
• Nuclear contents: chromatin (DNA complexed with histone and non-histone proteins, condensing into
chromosomes during cell division), and the nucleolus (a dense, non-membrane-bound region specialised for rRNA
transcription and ribosomal subunit assembly).
• Nuclear functions: houses and protects the genome (nuclear DNA); site of DNA replication and transcription
(mRNA, tRNA, rRNA synthesis); site of post-transcriptional RNA processing (splicing, capping, polyadenylation)
before export to cytoplasm; regulates gene expression.
• Clinical correlation: mitochondrial DNA mutations cause maternally inherited mitochondrial diseases (e.g.,
MELAS, MERRF) affecting high-energy-demand tissues (muscle, brain); nuclear pore/envelope and chromatin
abnormalities are implicated in laminopathies and certain cancers.
• Together, these organelles exemplify the functional compartmentalisation of the eukaryotic cell — the nucleus as
the genetic control centre, and the mitochondrion as the principal energy-transducing organelle.

Page 31
 Biochemistry Paper 1 — Short Notes

Vitamins & Nutrition

Q1. Vitamin B12 (6 marks)

Reference values: RDA: ~2.4 mcg/day (adults) | Normal serum B12: 200-900 pg/mL

• Vitamin B12 (Cobalamin) is a water-soluble vitamin containing a cobalt ion within a corrin ring; it is synthesised
only by microorganisms and obtained in the diet exclusively from animal sources (meat, fish, eggs, dairy) — a key
concern in strict vegetarians/vegans.
• Absorption: dietary B12 (protein-bound) is released by gastric acid/pepsin, binds to salivary R-protein
(haptocorrin) in the stomach, then in the duodenum is transferred to Intrinsic Factor (IF, secreted by gastric
parietal cells) after pancreatic proteases degrade R-protein; the B12-IF complex is absorbed in the terminal ileum
via specific cubam receptors.
• Absorbed B12 is transported in blood bound to transcobalamin II for delivery to tissues; the liver stores several
years' worth of B12, so deficiency typically takes years to manifest after absorption failure.
• Coenzyme forms and biochemical functions: Methylcobalamin is a cofactor for Methionine synthase, which
remethylates homocysteine to methionine (using methyl group from N5-methyl-THF, regenerating THF for
nucleotide synthesis) — deficiency causes the 'methyl folate trap'.
• Deoxyadenosylcobalamin is a cofactor for Methylmalonyl-CoA mutase, which converts methylmalonyl-CoA to
succinyl-CoA (important in odd-chain fatty acid and branched-chain amino acid catabolism, feeding into the TCA
cycle).
• Deficiency causes: Megaloblastic anaemia (due to impaired DNA synthesis from disrupted folate/nucleotide
metabolism — identical haematological picture to folate deficiency), and uniquely, neurological manifestations —
subacute combined degeneration of the spinal cord (demyelination due to methylmalonyl-CoA/propionate
accumulation disrupting myelin lipid synthesis), causing peripheral neuropathy, ataxia, and paraesthesia.
• Common causes of deficiency: Pernicious anaemia (autoimmune destruction of parietal cells/anti-IF antibodies
causing IF deficiency), strict vegan diet, terminal ileal disease/resection (e.g., Crohn's disease), and chronic
metformin/PPI use.
• Diagnostic markers: low serum B12, raised serum homocysteine AND raised methylmalonic acid (MMA) — the
latter helps distinguish B12 deficiency from pure folate deficiency, where MMA remains normal; Schilling test
(historical) assessed absorption specifically.

Q2. Wald's visual cycle (6 marks)

• Wald's visual cycle (also called the rhodopsin cycle) describes the biochemical basis of vision, explaining how
Vitamin A (retinol) participates in light detection by rod photoreceptor cells of the retina.
• Rhodopsin, the visual pigment of rod cells, is formed by combination of the protein Opsin with 11-cis-retinal (the
aldehyde form of Vitamin A) via a Schiff base linkage.
• Upon absorption of a photon of light, 11-cis-retinal undergoes photoisomerisation to All-trans-retinal, causing a
conformational change in opsin through an intermediate called Metarhodopsin II (activated rhodopsin, also
termed 'bleaching').
• Metarhodopsin II activates the G-protein transducin, which activates cGMP phosphodiesterase, lowering
intracellular cGMP levels; this closes cGMP-gated Na+ channels, hyperpolarising the rod cell membrane and
generating a nerve impulse transmitted via the optic nerve — this is the molecular basis of phototransduction.
• Regeneration: All-trans-retinal is released from opsin and reduced to All-trans-retinol by retinal reductase; this
diffuses to the retinal pigment epithelium, where it is isomerised to 11-cis-retinol and then oxidised back to 11-
cis-retinal, which recombines with opsin to regenerate functional rhodopsin, completing the cycle.

Page 32
 Biochemistry Paper 1 — Short Notes
• A portion of all-trans-retinol may also enter the general circulation (bound to retinol-binding protein) if not
immediately recycled.
• Clinical significance: Vitamin A deficiency impairs regeneration of rhodopsin, causing Night blindness (Nyctalopia)
— inability to see in dim light — classically the earliest and most sensitive clinical sign of Vitamin A deficiency;
prolonged severe deficiency leads to xerophthalmia and irreversible corneal damage (keratomalacia).
• This cycle illustrates the essential, non-caloric, catalytic-like role of Vitamin A in the visual process, distinct from
its other roles in epithelial differentiation and immune function.

Q3. Causes, effects, and management of obesity (6 marks)

Reference values: BMI: Normal 18.5-22.9 | Overweight 23-24.9 | Obese >=25 (Asian cut-offs); Waist circumference (Asian): men
>90 cm, women >80 cm indicates central obesity

• Obesity is a state of excess body fat accumulation resulting from a chronic imbalance between energy intake and
energy expenditure, assessed using Body Mass Index (BMI = weight in kg / height in m^2).
• Causes — Primary (exogenous) obesity: most common; results from excess caloric intake relative to expenditure,
sedentary lifestyle, genetic predisposition (polygenic influences on appetite regulation, leptin signalling), and
environmental/behavioural factors (processed food, screen time).
• Causes — Secondary (endogenous) obesity: less common; due to underlying endocrine disorders —
hypothyroidism, Cushing's syndrome (excess cortisol), insulinoma, hypothalamic disorders (damage to satiety
centres), and certain drugs (corticosteroids, some antipsychotics/antidepressants).

Page 33
 Biochemistry Paper 1 — Short Notes
• Genetic syndromes: rare monogenic causes include Leptin deficiency/leptin receptor mutations, Melanocortin-4
receptor (MC4R) mutations, and syndromic obesity (Prader-Willi syndrome).
• Effects/complications: Metabolic — insulin resistance and Type 2 Diabetes Mellitus, dyslipidaemia, Metabolic
Syndrome, non-alcoholic fatty liver disease; Cardiovascular — hypertension, coronary artery disease, stroke;
Respiratory — obstructive sleep apnoea, obesity hypoventilation syndrome; Musculoskeletal — osteoarthritis;
Reproductive — PCOS, infertility; increased risk of certain cancers (endometrial, breast, colon) and psychosocial
morbidity.
• Assessment: BMI for general classification; Waist circumference/Waist-hip ratio for assessing central (visceral)
obesity, which carries higher metabolic risk than peripheral fat distribution.
• Management — Lifestyle: caloric restriction with balanced, nutritious diet, regular physical activity/exercise, and
behavioural modification.
• Management — Medical/surgical: pharmacotherapy (e.g., GLP-1 receptor agonists, orlistat) for select patients;
bariatric surgery for severe obesity (BMI >=40, or >=35 with comorbidities) unresponsive to conservative
measures; treatment of any underlying secondary cause.

Q4. Niacin — functions, roles in coenzymes, and pellagra manifestations (6 marks)

Reference values: RDA: ~14-16 mg/day (as niacin equivalents); Pellagra classically described by 3 D's (Dermatitis, Diarrhoea,
Dementia) + a 4th D (Death) if untreated

• Niacin (Vitamin B3, includes nicotinic acid and nicotinamide) is a water-soluble vitamin that can also be
endogenously synthesised from the essential amino acid Tryptophan (approximately 60 mg tryptophan yields 1
mg niacin), requiring Vitamin B6, riboflavin, and iron as cofactors for this conversion.
• Coenzyme forms: NAD+ (Nicotinamide Adenine Dinucleotide) and NADP+ (Nicotinamide Adenine Dinucleotide
Phosphate) — both function as essential coenzymes carrying hydride ions (H-) in oxidation-reduction reactions.
• NAD+ functions predominantly in catabolic (oxidative) pathways — glycolysis, TCA cycle, beta-oxidation, oxidative
phosphorylation (electron donor to Complex I of ETC) — generating ATP.
• NADP+/NADPH functions predominantly in anabolic (reductive biosynthetic) pathways — fatty acid synthesis,
cholesterol synthesis, and in antioxidant defence (maintaining reduced glutathione via glutathione reductase).
• Deficiency disease — Pellagra: classically described by the '3 Ds': Dermatitis (photosensitive, symmetrical
pigmented rash on sun-exposed areas — a 'Casal's necklace' pattern around the neck is characteristic), Diarrhoea
(due to mucosal atrophy of the GI tract), and Dementia (neuropsychiatric symptoms — confusion, irritability,
memory loss); a 4th 'D', Death, occurs if untreated.
• Causes of pellagra: dietary deficiency (maize/corn-based diets, since niacin in maize is present in a bound,
unavailable form and maize is also low in tryptophan), Hartnup disease (impaired tryptophan absorption),
carcinoid syndrome (excess tryptophan diverted to serotonin synthesis), and isoniazid therapy (interferes with
vitamin B6, needed for tryptophan-to-niacin conversion).
• Treatment: oral nicotinamide/niacin supplementation, along with correction of the underlying dietary or
associated cause.
• Excess/pharmacological use: high-dose nicotinic acid is used to lower LDL and triglycerides and raise HDL, but
causes cutaneous flushing (prostaglandin-mediated) as a common side effect.

Q5. Methyl folate trap — explain (6 marks)

• The 'methyl folate trap' is a biochemical phenomenon explaining how Vitamin B12 deficiency secondarily
produces a functional folate deficiency, despite normal or even elevated total body folate stores.
• Background: dietary folate is converted intracellularly to various one-carbon-substituted tetrahydrofolate (THF)
derivatives, which are essential cofactors for purine and thymidylate (pyrimidine) synthesis, required for DNA
replication.

Page 34
 Biochemistry Paper 1 — Short Notes
• N5-methyl-THF is the predominant circulating form of folate in plasma; however, this form must be converted
back to free THF (to be reused for other one-carbon transfer reactions such as thymidylate synthesis) by donating
its methyl group.
• The only enzyme capable of removing the methyl group from N5-methyl-THF is Methionine synthase, which
simultaneously transfers this methyl group to homocysteine, forming methionine — and critically, this enzyme
absolutely requires Methylcobalamin (Vitamin B12) as a cofactor.
• In Vitamin B12 deficiency, Methionine synthase activity is impaired; consequently, N5-methyl-THF cannot be
demethylated back to free THF.
• Folate becomes progressively 'trapped' in the metabolically unusable N5-methyl-THF form — a form that cannot
participate in purine or thymidylate synthesis — creating a functional intracellular folate deficiency even though
total folate levels/stores may be normal or high.
• Consequence: impaired DNA synthesis (due to functional folate deficiency) leads to Megaloblastic anaemia —
explaining why B12 deficiency and folate deficiency produce an identical haematological picture (megaloblastic,
macrocytic anaemia with hypersegmented neutrophils).
• Clinical importance: this explains why administering folic acid alone to a patient with unrecognised B12 deficiency
can correct the anaemia (by providing enough unmethylated folate through mass action) but will NOT correct —
and may even worsen or unmask — the neurological damage of B12 deficiency (subacute combined
degeneration), since it does not address the underlying methylmalonyl-CoA mutase-related pathway; hence B12
status must always be checked before/alongside folate supplementation.

Q6. Vitamin C — biochemical functions and clinical features of scurvy (6 marks)

Reference values: RDA: ~40-90 mg/day (adults, varies by guideline); higher requirement in smokers, pregnancy

• Vitamin C (Ascorbic acid) is a water-soluble vitamin and a potent biological reducing agent (antioxidant), not
synthesised endogenously in humans (unlike most other mammals, due to loss of the enzyme L-gulonolactone
oxidase) and must be obtained from citrus fruits, amla, guava, and green leafy vegetables.

Page 35
 Biochemistry Paper 1 — Short Notes
• Biochemical function 1 — Collagen synthesis: essential cofactor for Prolyl hydroxylase and Lysyl hydroxylase,
enzymes that hydroxylate proline and lysine residues in procollagen, a modification essential for proper triple
helix stability and collagen cross-linking.
• Biochemical function 2 — Antioxidant: scavenges free radicals/reactive oxygen species directly, and regenerates
the antioxidant form of Vitamin E (reduces the tocopheroxyl radical back to active tocopherol).
• Biochemical function 3 — Enhances intestinal absorption of dietary non-haem iron by reducing Fe3+ to the more
absorbable Fe2+ form, and by forming a soluble iron-ascorbate complex.
• Biochemical function 4 — Cofactor for other hydroxylation reactions: dopamine beta-hydroxylase
(norepinephrine synthesis), and enzymes involved in carnitine biosynthesis and bile acid synthesis (7-alpha-
hydroxylase).
• Biochemical function 5 — Supports immune function and acts as a cofactor for certain cytochrome P450 enzymes.
• Deficiency disease — Scurvy: results from impaired collagen synthesis/stability due to deficient proline/lysine
hydroxylation, producing weak, structurally unstable collagen, particularly affecting tissues with high collagen
turnover (blood vessels, gums, bone).
• Clinical features of scurvy: bleeding gums (gingival hypertrophy and bleeding), perifollicular haemorrhages and
petechiae, poor/delayed wound healing, corkscrew hairs, joint swelling/haemarthrosis, and in infants,
subperiosteal haemorrhages causing pseudoparalysis; anaemia may also occur (due to associated poor iron
absorption and chronic blood loss); treatment is with Vitamin C supplementation, producing rapid symptomatic
improvement.

Q7. Vitamin E — recommended dietary allowance (RDA), antioxidant functions,

and deficiency states (6 marks)
Reference values: RDA: ~15 mg (alpha-tocopherol equivalents)/day for adults

• Vitamin E is a fat-soluble vitamin comprising a group of compounds called tocopherols and tocotrienols, of which
alpha-tocopherol is the most biologically active form; dietary sources include vegetable oils, nuts, seeds, and
green leafy vegetables.
• Being fat-soluble, Vitamin E is absorbed along with dietary fat (requiring bile salts and pancreatic lipase) and
transported initially in chylomicrons, then redistributed via lipoproteins (VLDL/LDL) in circulation.
• Primary biochemical function — Antioxidant: Vitamin E is the major lipid-soluble, chain-breaking antioxidant
located within cell membranes and lipoproteins, protecting polyunsaturated fatty acids from lipid peroxidation by
scavenging peroxyl free radicals generated during oxidative stress.
• In neutralising a free radical, tocopherol itself is converted to the tocopheroxyl radical, which is then regenerated
back to active tocopherol by Vitamin C (ascorbic acid) — illustrating the cooperative antioxidant network between
fat-soluble and water-soluble vitamins.
• Vitamin E protects cell membranes (particularly RBC membranes) from oxidative damage, and works
synergistically with the selenium-dependent enzyme glutathione peroxidase in cellular antioxidant defence.
• Other proposed roles: modulation of immune function, inhibition of platelet aggregation, and possible anti-
atherogenic effects (though clinical trial evidence for cardiovascular benefit of supplementation has been
inconsistent).
• Deficiency states: uncommon in the general population due to widespread dietary availability, but occurs in
conditions of fat malabsorption (chronic pancreatic insufficiency, cholestatic liver disease, cystic fibrosis,
abetalipoproteinemia) and in premature infants (limited transplacental transfer/reserve).
• Clinical features of deficiency: haemolytic anaemia (due to increased RBC membrane fragility from unchecked
lipid peroxidation), particularly notable in premature infants; peripheral neuropathy, ataxia (spinocerebellar
degeneration), and areflexia due to damage to large-calibre axons in prolonged severe deficiency; retinopathy
may also occur.

Page 36
 Biochemistry Paper 1 — Short Notes
Q8. Basal Metabolic Rate (BMR) — normal value ranges and the physiological
factors that influence it (6 marks)
Reference values: Normal BMR: approximately 1 kcal/kg body weight/hour (about 1200-1800 kcal/day depending on body size,
sex, age)

• Basal Metabolic Rate (BMR) is the minimum amount of energy (heat) expended by the body to maintain essential
physiological functions (respiration, circulation, cellular metabolism, body temperature) at complete physical and
mental rest.
• Standard measurement conditions: measured in a post-absorptive state (12-14 hours after last meal), in a
thermoneutral environment, with the subject awake but lying supine, physically and mentally relaxed, and having
had adequate sleep the night before.
• Normal value: approximately 1 kcal/kg body weight/hour, translating to roughly 1200-1800 kcal/day in adults,
though exact values vary considerably with body size, composition, sex, and age; commonly measured/expressed
via indirect calorimetry (oxygen consumption) or estimated using standardised predictive equations (e.g., Harris-
Benedict).
• Factors increasing BMR: larger body surface area (BMR correlates better with surface area than weight alone),
younger age (higher in children/infants, declines with advancing age), male sex (greater lean muscle mass),
pregnancy and lactation, fever (BMR rises approximately 13% for each 1 degree C rise in temperature),
hyperthyroidism (thyroid hormones are major BMR determinants), and increased sympathetic
activity/catecholamines (stress, exercise recovery).
• Factors decreasing BMR: starvation/prolonged fasting (adaptive reduction to conserve energy), hypothyroidism,
advancing age (decreasing lean body mass), sleep, and malnutrition.
• Body composition strongly influences BMR: lean (muscle) tissue is far more metabolically active than adipose
tissue, so individuals with greater muscle mass have proportionately higher BMR.
• Hormonal regulation: thyroid hormones (T3/T4) are the principal long-term regulators of BMR by increasing
Na+/K+-ATPase activity and mitochondrial oxidative metabolism in most tissues; growth hormone and
catecholamines also contribute to short-term elevations.
• Clinical relevance: BMR estimation/measurement assists in calculating total daily energy requirements (BMR x
activity factor) for nutritional planning, and altered BMR is a useful clinical clue in thyroid disorders (elevated in
hyperthyroidism, reduced in hypothyroidism).

Q9. Nutritional requirements: Components of a Balanced Diet and determining

total energy needs based on occupational workload (6 marks)
Reference values: Sedentary: ~1.4-1.5x BMR | Moderate: ~1.6-1.7x BMR | Heavy work: ~1.9-2.2x BMR (activity factors,
approximate ICMR/WHO guidance)

• A Balanced Diet is one that provides all essential nutrients — carbohydrates, proteins, fats, vitamins, minerals,
and adequate water/fibre — in appropriate proportions and quantities to meet an individual's physiological
needs, while maintaining health and preventing both deficiency and excess.
• Macronutrient distribution (as approximate percentage of total caloric intake): Carbohydrates 55-65%, Fats 20-
30%, Proteins 10-15% of total energy, with adequate essential fatty acids and essential amino acids ensured.
• Protein requirement: approximately 0.8-1 g/kg body weight/day for a sedentary adult (ICMR recommendations),
with higher requirements during growth, pregnancy, lactation, and illness/recovery; should include adequate
proportion of high biological value (complete) protein.
• Micronutrients: adequate intake of vitamins (fat-soluble A, D, E, K; water-soluble B-complex, C) and minerals
(calcium, iron, iodine, zinc) must be ensured, along with dietary fibre (aids digestion, glycaemic control, and lipid
metabolism) and adequate water intake.
• Total daily energy requirement = BMR x Physical Activity Level (activity factor), reflecting that BMR alone accounts
only for resting energy needs, while additional calories are needed for physical work/activity.

Page 37
 Biochemistry Paper 1 — Short Notes
• Occupational workload categories (approximate activity factors applied to BMR): Sedentary work (desk job,
minimal physical activity) — around 1.4-1.5x BMR; Moderate work (light industrial work, walking, moderate
physical activity) — around 1.6-1.7x BMR; Heavy work (manual labour, farming, construction) — around 1.9-2.2x
BMR.
• Additional adjustments: energy requirements increase further during pregnancy (additional ~300 kcal/day in later
trimesters) and lactation (additional ~500 kcal/day), and vary with age, body size, and climate.
• Practical application: dietary planning for specific occupational groups (e.g., manual labourers vs. sedentary office
workers) must account for these differing activity-based energy needs to prevent both undernutrition and
obesity, forming the basis of individualised nutritional counselling and public health dietary guidelines (e.g., ICMR-
NIN recommended dietary allowances).

Q10. Biotin (Vitamin B7) and Riboflavin (Vitamin B2) — metabolic roles and
respective deficiency features (6 marks)
Reference values: Biotin RDA: ~30 mcg/day | Riboflavin RDA: ~1.1-1.3 mg/day

• Biotin (Vitamin B7/H) is a water-soluble vitamin that functions as an essential coenzyme covalently bound (via an
amide linkage to a lysine residue) to several carboxylase enzymes, enabling them to fix CO2 onto substrates.
• Biotin-dependent carboxylases: Pyruvate carboxylase (pyruvate -> oxaloacetate; gluconeogenesis/anaplerosis),
Acetyl-CoA carboxylase (acetyl-CoA -> malonyl-CoA; rate-limiting step of fatty acid synthesis), Propionyl-CoA
carboxylase (propionyl-CoA -> methylmalonyl-CoA; odd-chain fatty acid/branched amino acid catabolism), and
Pyruvate/beta-methylcrotonyl-CoA carboxylase pathways.
• Biotin deficiency is rare (synthesised by gut flora, widely available in diet) but can occur with prolonged
consumption of raw egg white, which contains Avidin — a protein that binds biotin with extremely high affinity,
preventing its intestinal absorption (avidin is denatured/inactivated by cooking).
• Features of biotin deficiency: dermatitis (scaly, erythematous rash), alopecia (hair loss), glossitis, and neurological
symptoms (paraesthesia, depression, lethargy) in severe/prolonged deficiency.
• Riboflavin (Vitamin B2) is a water-soluble vitamin, precursor to the coenzymes FMN (Flavin Mononucleotide) and
FAD (Flavin Adenine Dinucleotide), which function as essential hydrogen/electron carriers in numerous oxidation-
reduction reactions.
• FAD/FMN-dependent reactions: Succinate dehydrogenase (TCA cycle/Complex II of ETC), Acyl-CoA dehydrogenase
(fatty acid beta-oxidation), NADH dehydrogenase (Complex I of ETC), Glutathione reductase (regenerates reduced
glutathione, linking riboflavin status to antioxidant defence), and Pyruvate dehydrogenase/alpha-ketoglutarate
dehydrogenase complexes.
• Riboflavin deficiency (Ariboflavinosis) features: Angular stomatitis (cracking/fissuring at corners of mouth),
Cheilosis (lip fissuring), Glossitis (magenta-coloured tongue), seborrheic dermatitis (particularly nasolabial folds),
and Corneal vascularisation with photophobia; often occurs together with deficiencies of other B-complex
vitamins.
• Both deficiencies are diagnosed largely clinically (characteristic mucocutaneous findings) and respond promptly to
appropriate vitamin supplementation; riboflavin deficiency can also secondarily impair niacin synthesis from
tryptophan (riboflavin is a required cofactor in that pathway) and impair activation of Vitamin B6.

Page 38
 Biochemistry Paper 1 — Short Notes

General & Communication (AETCOM)

Q1. Role of a physician towards society and community (6 marks)

• A physician's role extends well beyond individual patient treatment to encompass broader responsibilities
towards society and the community, reflecting the social contract between the medical profession and the public
it serves.
• Healer and care provider: primary role of diagnosing and treating illness with competence, compassion, and up-
to-date evidence-based knowledge, respecting patient autonomy and dignity.
• Health educator: educating patients, families, and the community on disease prevention, healthy lifestyle
practices, immunisation, nutrition, and early recognition of illness — extending impact beyond the clinic.
• Preventive and public health role: participating in disease surveillance, outbreak reporting, immunisation drives,
screening programs, and health promotion campaigns, contributing to reducing community disease burden.
• Communicator and counsellor: providing clear, empathetic, culturally sensitive communication, especially
regarding diagnosis, prognosis, and treatment options, enabling informed shared decision-making.
• Role as a scientist/lifelong learner: staying updated through continuing medical education, and contributing to
research and evidence generation that benefits the wider community.
• Advocate for community health: participating in health policy discussions, addressing social determinants of
health (poverty, sanitation, occupational hazards), and advocating for equitable, accessible healthcare,
particularly for underserved populations.
• Professional and ethical conduct: maintaining confidentiality, informed consent, honesty, and integrity; serving as
a role model and leader within the community, upholding public trust in the medical profession, and practising
within the framework of medical ethics and applicable law (e.g., Indian Medical Council/National Medical
Commission regulations).

Q2. Effective clinical communication: How to empathetically reveal an elevated

blood sugar or cholesterol report to a patient and counsel them on the strict
necessity of therapeutic compliance (6 marks)
• Effective delivery of abnormal laboratory results requires a structured, empathetic approach that balances
honest, accurate information with sensitivity to the patient's emotional response — often guided by frameworks
such as SPIKES (Setting, Perception, Invitation, Knowledge, Empathy, Summary/Strategy) adapted for non-cancer
'bad news' scenarios.
• Setting: ensure privacy, adequate time, comfortable seating (avoid a rushed or public setting), and give full
attention (avoid interruptions, phones).
• Perception: begin by assessing what the patient already knows or suspects ('What do you understand about why
we did this blood test?'), to tailor the explanation appropriately.
• Invitation/permission: ask if they are ready to discuss the results now, respecting their readiness and pace.
• Knowledge — deliver information clearly: use simple, jargon-free language (avoid purely technical terms like
'HbA1c' or 'LDL' without explanation), give the information in small chunks, check understanding periodically
('teach-back' method), and avoid overwhelming the patient with excessive detail at once.
• Empathy: acknowledge and validate emotional reactions (worry, denial, frustration) with reflective statements ('I
can see this is concerning news'), allow silence/time to process, and avoid being dismissive or purely
clinical/mechanical in tone.
• Strategy and counselling on compliance: explain the report findings, associated risks if untreated (in a balanced,
non-alarming way), and the concrete benefits of treatment adherence; involve the patient in shared decision-

Page 39
 Biochemistry Paper 1 — Short Notes
making regarding lifestyle modification and medication plans, addressing barriers to compliance (cost, side-
effects, misconceptions) directly.
• Summary and follow-up: summarise the plan clearly, provide written instructions if possible, arrange appropriate
follow-up, and offer an open channel for questions — reinforcing that long-term partnership and regular
monitoring (not one-time advice) are essential for successful management of chronic conditions such as diabetes
and dyslipidaemia.

Page 40